LON:AGY - Allergy Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 24.90
▼ -0.6 (-2.35%)
1 month | 3 months | 12 months
Get New Allergy Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Allergy Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 24.90.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Allergy Therapeutics. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/15/2020FinnCapReiterated RatingCorporate
i
7/9/2020FinnCapReiterated RatingCorporate
i
6/24/2020FinnCapReiterated RatingCorporate
i
3/4/2020FinnCapReiterated RatingCorporate
i
2/3/2020FinnCapReiterated RatingCorporate
i
1/16/2020FinnCapReiterated RatingCorporate
i
11/28/2019FinnCapReiterated RatingCorporate
i
9/25/2019FinnCapReiterated RatingCorporate
i
7/11/2019FinnCapReiterated RatingCorporate
i
6/28/2019FinnCapReiterated RatingCorporate
i
4/29/2019FinnCapReiterated RatingCorporate
i
3/22/2019FinnCapLower Price TargetCorporateGBX 47 ➝ GBX 40
i
3/18/2019Numis SecuritiesReiterated RatingBuyGBX 35
i
3/6/2019Numis SecuritiesReiterated RatingBuyGBX 45
i
3/6/2019FinnCapReiterated RatingCorporate
i
1/16/2019FinnCapReiterated RatingCorporate
i
9/27/2018FinnCapReiterated RatingCorporate
i
9/26/2018Numis SecuritiesReiterated RatingBuyGBX 45
i
7/19/2018Numis SecuritiesReiterated RatingBuy
i
7/12/2018FinnCapReiterated RatingCorporate
i
5/21/2018Numis SecuritiesReiterated RatingBuy
i
5/21/2018FinnCapReiterated RatingCorporate
i
3/7/2018Numis SecuritiesReiterated RatingBuyGBX 45
i
3/7/2018FinnCapReiterated RatingCorporateGBX 47
i
2/28/2018FinnCapReiterated RatingCorporateGBX 47
i
2/12/2018FinnCapReiterated RatingCorporateGBX 47
i
2/1/2018FinnCapReiterated RatingCorporateGBX 47
i
1/31/2018Numis SecuritiesReiterated RatingBuyGBX 45
i
12/5/2017Numis SecuritiesReiterated RatingBuyGBX 45
i
11/21/2017FinnCapReiterated RatingBuyGBX 47
i
10/20/2017FinnCapReiterated RatingBuyGBX 47
i
9/28/2017Panmure GordonReiterated RatingBuy
i
9/28/2017Numis SecuritiesReiterated RatingBuyGBX 45
i
9/28/2017FinnCapBoost Price TargetBuyGBX 46 ➝ GBX 47
i
9/22/2017Numis SecuritiesReiterated RatingBuyGBX 45
i
9/18/2017Panmure GordonReiterated RatingBuy
i
8/24/2017FinnCapReiterated RatingBuyGBX 46
i
7/18/2017Numis SecuritiesReiterated RatingBuyGBX 45
i
7/18/2017FinnCapBoost Price TargetBuyGBX 43 ➝ GBX 46
i
5/30/2017FinnCapReiterated RatingBuyGBX 43
i
4/20/2017Panmure GordonReiterated RatingBuyGBX 53
i
4/4/2017Numis SecuritiesBoost Price TargetBuyGBX 37 ➝ GBX 45
i
4/4/2017Stifel NicolausReiterated RatingBuyGBX 60
i
3/29/2017FinnCapReiterated RatingBuyGBX 43
i
3/16/2017FinnCapReiterated RatingBuyGBX 43
i
2/24/2017FinnCapReiterated RatingBuyGBX 43
i
2/14/2017Panmure GordonReiterated RatingBuyGBX 53
i
2/14/2017Stifel NicolausReiterated RatingBuyGBX 60
i
2/14/2017FinnCapReiterated RatingBuyGBX 43
i
2/1/2017Panmure GordonReiterated RatingBuyGBX 53
i
2/1/2017FinnCapReiterated RatingBuyGBX 43
i
1/26/2017Panmure GordonReiterated RatingBuyGBX 53
i
1/19/2017Numis SecuritiesReiterated RatingBuyGBX 37
i
1/19/2017FinnCapBoost Price TargetBuyGBX 40 ➝ GBX 43
i
1/19/2017Panmure GordonReiterated RatingBuyGBX 53
i
1/6/2017FinnCapInitiated CoverageBuyGBX 40
i
11/2/2016Panmure GordonReiterated RatingBuyGBX 53
i
10/10/2016Numis SecuritiesReiterated RatingBuyGBX 37
i
10/10/2016Panmure GordonReiterated RatingBuyGBX 53
i
9/27/2016Numis SecuritiesReiterated RatingBuyGBX 37
i
9/26/2016Panmure GordonReiterated RatingBuyGBX 53
i
9/21/2016Numis SecuritiesInitiated CoverageBuyGBX 37
i
7/14/2016Panmure GordonReiterated RatingBuyGBX 53
i
7/8/2016Stifel NicolausReiterated RatingBuyGBX 72
i
7/8/2016Panmure GordonReiterated RatingBuyGBX 53
i
(Data available from 6/14/2016 forward)
Allergy Therapeutics logo
Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Read More

Today's Range

Now: GBX 24.90
24.90
25.40

50 Day Range

MA: GBX 23.14
20.50
26.10

52 Week Range

Now: GBX 24.90
11
26.50

Volume

96,455 shs

Average Volume

340,307 shs

Market Capitalization

£159.80 million

P/E Ratio

24.90

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Allergy Therapeutics?

The following Wall Street sell-side analysts have issued reports on Allergy Therapeutics in the last year: FinnCap.
View the latest analyst ratings for AGY.

What is the current price target for Allergy Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Allergy Therapeutics in the last year. has the lowest price target set, forecasting a price of £100,000 for Allergy Therapeutics in the next year.
View the latest price targets for AGY.

What is the current consensus analyst rating for Allergy Therapeutics?

Allergy Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGY.

What other companies compete with Allergy Therapeutics?

How do I contact Allergy Therapeutics' investor relations team?

Allergy Therapeutics' physical mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company's listed phone number is +44-1903-844700. The official website for Allergy Therapeutics is www.allergytherapeutics.com.